> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# MimiVax to Seek FDA Meeting on Glioblastoma Vaccine
- URL: https://www.fdaweb.com/mimivax-to-seek-fda-meeting-on-glioblastoma-vaccine/
- Published: 2026-10-08T00:38:57.000Z
- Updated: 2026-10-08T00:38:57.000Z
- Author: David McFarland
- Tags: Biologics

MimiVax says it plans to seek a meeting with FDA to review positive results from its Phase 2b SURVIVE trial of SurVaxM, a novel cancer vaccine for patients with newly diagnosed glioblastoma. In a statement, company officials say they want to use the meeting to review the SURVIVE data and align on a path forward.

The statement says that across all 233 evaluable patients in the trial, SurVaxM improved median overall survival, the primary endpoint, to 22.8 months, compared to 22 months for placebo. Importantly, it says that, among a prespecified subpopulation of patients aged 65 and under, the vaccine demonstrated a statistically significant benefit, with median overall survival of 24.2 months versus 20.2 months. A significant benefit was also seen in the same patient subgroup for progression-free survival, it says.

The company says SurVaxM was well tolerated, with no treatment-related deaths in either trial arm.